Immune regulation by atypical chemokine receptors

Nature Reviews Immunology

Volumn 13, Issue 11, 2013, Pages 815-829

  Nibbs, Robert J B ^a   Graham, Gerard J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; G PROTEIN COUPLED RECEPTOR;

DEVELOPMENT; HOMEOSTASIS; HUMAN; IMMUNOREGULATION; INFECTION; INFLAMMATION; INFLAMMATORY DISEASE; LEUKOCYTE MIGRATION; LIGAND BINDING; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; CHEMOKINES; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY; IMMUNOMODULATION; INFECTION; INFLAMMATION; LIGANDS; NEOPLASMS; PROTEIN BINDING; RECEPTORS, CHEMOKINE;

EID: 84886768227     PISSN: 14741733     EISSN: 14741741     Source Type: Journal    
DOI: 10.1038/nri3544     Document Type: Review

References (200)

1. Zlotnik, A. & Yoshie, O. The chemokine superfamily revisited. Immunity 36, 705-716 (2012).
2. Rot, A. & von Andrian, U. H. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu. Rev. Immunol. 22, 891-928 (2004). (Pubitemid 38680444)
3. Hansell, C. A. H., Hurson, C. E. & Nibbs, R. J. B. DARC and D6: silent partners in chemokine regulation? Immunol. Cell Biol. 89, 197-206 (2011).
4. Graham, G. J., Locati, M., Mantovani, A., Rot, A. & Thelen, M. The biochemistry and biology of the atypical chemokine receptors. Immunol. Lett. 145, 30-38 (2012).
5. Bachelerie, F. et al. International Union of Pharmacology. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. (in the press).
6. Mantovani, A., Bonecchi, R. & Locati, M. Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nature Rev. Immunol. 6, 907-918 (2006). (Pubitemid 44851733)
7. Gardner, L., Patterson, A. M., Ashton, B. A., Stone, M. A. & Middleton, J. The human Duffy antigen binds selected inflammatory but not homeostatic chemokines. Biochem. Biophys. Res. Commun. 321, 306-312 (2004). (Pubitemid 39055746)
8. Nibbs, R. J., Wylie, S. M., Pragnell, I. B. & Graham, G. J. Cloning and characterization of a novel murine β-chemokine receptor, D6. Comparison to three other related macrophage inflammatory protein-1α-receptors, CCR-1, CCR-3, and CCR-5. J. Biol. Chem. 272, 12495-12504 (1997). (Pubitemid 27203340)
9. Nibbs, R. J., Wylie, S. M., Yang, J., Landau, N. R. & Graham, G. J. Cloning and characterization of a novel promiscuous human β-chemokine receptor D6. J. Biol. Chem. 272, 32078-32083 (1997). (Pubitemid 28011878)
10. Bonini, J. A. & Steiner, D. F. Molecular cloning and expression of a novel rat CC-chemokine receptor (rCCR10rR) that binds MCP-1 and MIP-1β with high affinity. DNA Cell Biol. 16, 1023-1030 (1997). (Pubitemid 28062960)
11. Bonecchi, R. et al. Differential recognition and scavenging of native and truncated macrophage-derived chemokine (macrophage-derived chemokine/CC chemokine ligand 22) by the D6 decoy receptor. J. Immunol. 172, 4972-4976 (2004). (Pubitemid 38456423)
12. Savino, B. et al. Recognition versus adaptive up-regulation and degradation of CC chemokines by the chemokine decoy receptor D6 are determined by their N-terminal sequence. J. Biol. Chem. 284, 26207-26215 (2009).
13. Nibbs, R. J., Yang, J., Landau, N. R., Mao, J. H. & Graham, G. J. LD78β, a non-allelic variant of human MIP-1α (LD78α), has enhanced receptor interactions and potent HIV suppressive activity. J. Biol. Chem. 274, 17478-17483 (1999).
14. Hansell, C. A. H. et al. Universal expression and dual function of the atypical chemokine receptor D6 on innate-like B cells in mice. Blood 117, 5413-5424 (2011).
15. Burns, J. M. et al. A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development. J. Exp. Med. 203, 2201-2213 (2006). (Pubitemid 44352240)
16. Balabanian, K. et al. The chemokine SDF-1/CXCL12 binds to and signals through the orphan receptor RDC1 in T lymphocytes. J. Biol. Chem. 280, 35760-35766 (2005). (Pubitemid 41532769)
17. Townson, J. R. & Nibbs, R. J. B. Characterization of mouse CCX-CKR, a receptor for the lymphocyte-attracting chemokines TECK/mCCL25, SLC/mCCL21 and MIP-3β/mCCL19: comparison to human CCX-CKR. Eur. J. Immunol. 32, 1230-1241 (2002). (Pubitemid 34546250)
18. Gosling, J. et al. Cutting edge: identification of a novel chemokine receptor that binds dendritic cell-and T cell-active chemokines including ELC, SLC, and TECK. J. Immunol. 164, 2851-2856 (2000). (Pubitemid 30148939)
19. Watts, A. O. et al. β-arrestin recruitment and G protein signaling by the atypical human chemokine decoy receptor CCX-CKR. J. Biol. Chem. 288, 7169-7181 (2013).
20. Bondue, B., Wittamer, V. & Parmentier, M. Chemerin and its receptors in leukocyte trafficking, inflammation and metabolism. Cytokine Growth Factor Rev. 22, 331-338 (2011).
21. Leick, M. et al. CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B. Immunology 129, 536-546 (2010).
22. Hartmann, T. N. et al. Human B cells express the orphan chemokine receptor CRAM-A/B in a maturation-stage-dependent and CCL5-modulated manner. Immunology 125, 252-262 (2008).
23. McCulloch, C. V. et al. Multiple roles for the C-terminal tail of the chemokine scavenger D6. J. Biol. Chem. 283, 7972-7982 (2008).
24. Weber, M. et al. The chemokine receptor D6 constitutively traffics to and from the cell surface to internalize and degrade chemokines. Mol. Biol. Cell 15, 2492-2508 (2004). (Pubitemid 38580663)
25. Galliera, E. et al. β-arrestin-dependent constitutive internalization of the human chemokine decoy receptor D6. J. Biol. Chem. 279, 25590-25597 (2004). (Pubitemid 38756820)
26. Fra, A. M. et al. Cutting edge: scavenging of inflammatory CC chemokines by the promiscuous putatively silent chemokine receptor D6. J. Immunol. 170, 2279-2282 (2003). (Pubitemid 36245612)
27. Madigan, J. et al. Chemokine scavenger D6 is expressed by trophoblasts and AIDS the survival of mouse embryos transferred into allogeneic recipients. J. Immunol. 184, 3202-3212 (2010).
28. Bonecchi, R. et al. Regulation of D6 chemokine scavenging activity by ligand-and Rab11-dependent surface up-regulation. Blood 112, 493-503 (2008).
29. Borroni, E. M. et al. β-arrestin-dependent activation of the cofilin pathway is required for the scavenging activity of the atypical chemokine receptor D6. Sci. Signal. 6, ra30 (2013).
30. Hoffmann, F. et al. Rapid uptake and degradation of CXCL12 depend on CXCR7 carboxyl-terminal serine/threonine residues. J. Biol. Chem. 287, 28362-28377 (2012).
31. Luker, K. E., Steele, J. M., Mihalko, L. A., Ray, P. & Luker, G. D. Constitutive and chemokine-dependent internalization and recycling of CXCR7 in breast cancer cells to degrade chemokine ligands. Oncogene 29, 4599-4610 (2010).
32. Naumann, U. et al. CXCR7 Functions as a scavenger for CXCL12 and CXCL11. PLoS ONE 5, e9175 (2010).
33. Comerford, I., Milasta, S., Morrow, V., Milligan, G. & Nibbs, R. The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro. Eur. J. Immunol. 36, 1904-1916 (2006). (Pubitemid 44089056)
34. Heinzel, K., Benz, C. & Bleul, C. C. A silent chemokine receptor regulates steady-state leukocyte homing in vivo. Proc. Natl Acad. Sci. USA 104, 8421-8426 (2007). (Pubitemid 47175503)
35. Canals, M. et al. Ubiquitination of CXCR7 controls receptor trafficking. PLoS ONE 7, e34192 (2012).
36. Sánchez-Alcañiz, J. A. et al. Cxcr7 controls neuronal migration by regulating chemokine responsiveness. Neuron 69, 77-90 (2011).
37. Ray, P. et al. Carboxy-terminus of CXCR7 regulates receptor localization and function. Int. J. Biochem. Cell Biol. 44, 669-678 (2012).
38. Rajagopal, S. et al. β-arrestin-but not G protein-mediated signaling by the 'decoy' receptor CXCR7. Proc. Natl Acad. Sci. USA 107, 628-632 (2010).
39. Kalatskaya, I. et al. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol. Pharmacol. 75, 1240-1247 (2009).
40. Zabel, B. A. et al. Elucidation of CXCR7-mediated signaling events and inhibition of CXCR4-mediated tumor cell transendothelial migration by CXCR7 ligands. J. Immunol. 183, 3204-3211 (2009).
41. Luker, K. E., Gupta, M., Steele, J. M., Foerster, B. R. & Luker, G. D. Imaging ligand-dependent activation of CXCR7. Neoplasia 11, 1022-1035 (2009).
42. Mahabaleshwar, H., Tarbashevich, K., Nowak, M., Brand, M. & Raz, E. β-arrestin control of late endosomal sorting facilitates decoy receptor function and chemokine gradient formation. Development 139, 2897-2902 (2012).
43. Kumar, R. et al. CXCR7 mediated Giα independent activation of ERK and Akt promotes cell survival and chemotaxis in T cells. Cell. Immunol. 272, 230-241 (2011).
44. Odemis, V., Boosmann, K., Heinen, A., Küry, P. & Engele, J. CXCR7 is an active component of SDF-1 signalling in astrocytes and Schwann cells. J. Cell Sci. 123, 1081-1088 (2010).
45. Göttle, P. et al. Activation of CXCR7 receptor promotes oligodendroglial cell maturation. Ann. Neurol. 68, 915-924 (2010).
46. Lipfert, J., Odemis, V. & Engele, J. Grk2 is an essential regulator of CXCR7 signalling in astrocytes. Cell. Mol. Neurobiol. 33, 111-118 (2012).
47. Singh, R. K. & Lokeshwar, B. L. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth. Cancer Res. 71, 3268-3277 (2011).
48. Liberman, J. et al. Involvement of the CXCR7/CXCR4/CXCL12 axis in the malignant progression of human neuroblastoma. PLoS ONE 7, e43665 (2012).
49. Wang, Y. et al. CXCR4 and CXCR7 have distinct functions in regulating interneuron migration. Neuron 69, 61-76 (2011).
50. Odemis, V. et al. The presumed atypical chemokine receptor CXCR7 signals through G(i/o) proteins in primary rodent astrocytes and human glioma cells. Glia 60, 372-381 (2012).
51. Heinrich, E. L., Lee, W., Lu, J., Lowy, A. M. & Kim, J. Chemokine CXCL12 activates dual CXCR4 and CXCR7-mediated signaling pathways in pancreatic cancer cells. J. Trans. Med. 10, 68 (2012).
52. Hattermann, K. et al. The chemokine receptor CXCR7 is highly expressed in human glioma cells and mediates antiapoptotic effects. Cancer Res. 70, 3299-3308 (2010).
53. Costello, C. M. et al. A role for the CXCL12 receptor, CXCR7, in the pathogenesis of human pulmonary vascular disease. Eur. Respir. J. 39, 1415-1424 (2012).
54. Luker, K. E., Gupta, M. & Luker, G. D. Imaging chemokine receptor dimerization with firefly luciferase complementation. FASEB J. 23, 823-834 (2009).
55. + cells. J. Leukoc. Biol. 84, 1130-1140 (2008).
56. Décaillot, F. M. et al. CXCR7/CXCR4 heterodimer constitutively recruits β-arrestin to enhance cell migration. J. Biol. Chem. 286, 32188-32197 (2011).
57. Sierro, F. et al. Disrupted cardiac development but normal hematopoiesis in mice deficient in the second CXCL12/SDF-1 receptor, CXCR7. Proc. Natl Acad. Sci. USA 104, 14759-14764 (2007). (Pubitemid 350003216)
58. Levoye, A., Balabanian, K., Baleux, F., Bachelerie, F. & Lagane, B. CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling. Blood 113, 6085-6093 (2009).
59. Chakera, A., Seeber, R. M., John, A. E., Eidne, K. A. & Greaves, D. R. The Duffy antigen/receptor for chemokines exists in an oligomeric form in living cells and functionally antagonizes CCR5 signaling through hetero-oligomerization. Mol. Pharmacol. 73, 1362-1370 (2008). (Pubitemid 351574826)
60. Rot, A. et al. Cell-autonomous regulation of neutrophil migration by the D6 chemokine decoy receptor. J. Immunol. 190, 6450-6456 (2013).
61. Zhao, Y. et al. Duffy antigen receptor for chemokines mediates chemokine endocytosis through a macropinocytosis-like process in endothelial cells. PLoS ONE 6, e29624 (2011).
62. Pruenster, M. et al. The Duffy antigen receptor for chemokines transports chemokines and supports their promigratory activity. Nature Immunol. 10, 101-108 (2009).
63. Lee, J. S. et al. Duffy antigen facilitates movement of chemokine across the endothelium in vitro and promotes neutrophil transmigration in vitro and in vivo. J. Immunol. 170, 5244-5251 (2003). (Pubitemid 36554758)
64. Martinez de la Torre, Y. et al. Protection against inflammation-and autoantibody-caused fetal loss by the chemokine decoy receptor D6. Proc. Natl Acad. Sci. USA 104, 2319-2324 (2007).
65. Bordon, Y. et al. The atypical chemokine receptor D6 contributes to the development of experimental colitis. J. Immunol. 182, 5032-5040 (2009).
66. Kin, N. W., Crawford, D. M., Liu, J., Behrens, T. W. & Kearney, J. F. DNA microarray gene expression profile of marginal zone versus follicular B cells and idiotype positive marginal zone B cells before and after immunization with Streptococcus pneumoniae. J. Immunol. 180, 6663-6674 (2008).
67. Infantino, S., Moepps, B. & Thelen, M. Expression and regulation of the orphan receptor RDC1 and its putative ligand in human dendritic and B cells. J. Immunol. 176, 2197-2207 (2006). (Pubitemid 43201667)
68. Berahovich, R. D. et al. CXCR7 protein is not expressed on human or mouse leukocytes. J. Immunol. 185, 5130-5139 (2010).
69. Humpert, M.-L. et al. Complementary methods provide evidence for the expression of CXCR7 on human B cells. Proteomics 12, 1938-1948 (2012).
70. Wang, H. et al. The CXCR7 chemokine receptor promotes B-cell retention in the splenic marginal zone and serves as a sink for CXCL12. Blood 119, 465-468 (2011).
71. Cruz-Orengo, L. et al. CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunity. J. Exp. Med. 208, 327-339 (2011).
72. Winkelmann, R. et al. B cell homeostasis and plasma cell homing controlled by Krüppel-like factor 2. Proc. Natl Acad. Sci. USA 108, 710-715 (2011).
73. McKimmie, C. S. et al. Hemopoietic cell expression of the chemokine decoy receptor D6 is dynamic and regulated by GATA1. J. Immunol. 181, 3353-3363 (2008).
74. Vetrano, S. et al. The lymphatic system controls intestinal inflammation and inflammation-associated colon cancer through the chemokine decoy receptor D6. Gut 59, 197-206 (2010).
75. Bazzan, E. et al. Expression of the atypical chemokine receptor D6 in human alveolar macrophages in COPD. Chest 143, 98-106 (2012).
76. Nibbs, R. J. et al. The β-chemokine receptor D6 is expressed by lymphatic endothelium and a subset of vascular tumors. Am. J. Pathol. 158, 867-877 (2001). (Pubitemid 32221780)
77. Malhotra, D. et al. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature Immunol. 13, 499-510 (2012).
78. Di Liberto, D. et al. Role of the chemokine decoy receptor D6 in balancing inflammation, immune activation, and antimicrobial resistance in Mycobacterium tuberculosis infection. J. Exp. Med. 205, 2075-2084 (2008).
79. Singh, M. D. et al. Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis. Am. J. Pathol. 181, 1158-1164 (2012).
80. Nibbs, R. J. B. et al. The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors. J. Clin. Invest. 117, 1884-1892 (2007). (Pubitemid 47036322)
81. Wick, N. et al. Lymphatic precollectors contain a novel, specialized subpopulation of podoplanin low, CCL27-expressing lymphatic endothelial cells. Am. J. Pathol. 173, 1202-1209 (2008).
82. Gerrits, H. et al. Early postnatal lethality and cardiovascular defects in CXCR7-deficient mice. Genesis 46, 235-245 (2008). (Pubitemid 351961759)
83. Neusser, M. A. et al. The chemokine receptor CXCR7 is expressed on lymphatic endothelial cells during renal allograft rejection. Kidney Int. 77, 801-808 (2010).
84. Watanabe, K. et al. Pathogenic role of CXCR7 in rheumatoid arthritis. Arthritis Rheum. 62, 3211-3220 (2010).
85. Miao, Z. et al. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc. Natl Acad. Sci. USA 104, 15735-15740 (2007). (Pubitemid 350035369)
86. Luker, K. E. et al. Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells. Oncogene 31, 4750-4758 (2012).
87. Gebauer, F. et al. Prognostic impact of CXCR4 and CXCR7 expression in pancreatic adenocarcinoma. J. Surg. Oncol. 104, 140-145 (2011).
88. Monnier, J. et al. CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. Eur. J. Cancer 48, 138-148 (2012).
89. Guillemot, E. et al. CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver. Br. J. Cancer 107, 1944-1949 (2012).
90. Maishi, N. et al. CXCR7: A novel tumor endothelial marker in renal cell carcinoma. Pathol. Int. 62, 309-317 (2012).
91. Schanz, A. et al. CXCR7 and syndecan-4 are potential receptors for CXCL12 in human cytotrophoblasts. J. Reprod. Immunol. 89, 18-25 (2011).
92. Wiederholt, T. & Wasmuth, H. E. Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. Hum. Immunol. 69, 861-866 (2008).
93. Berres, M.-L. et al. The chemokine scavenging receptor D6 limits acute toxic liver injury in vivo. Biol. Chem. 390, 1039-1045 (2009).
94. Bunting, M. D. et al. CCX-CKR deficiency alters thymic stroma impairing thymocyte development and promoting autoimmunity. Blood 121, 118-128 (2013).
95. Rode, I. & Boehm, T. Regenerative capacity of adult cortical thymic epithelial cells. Proc. Natl Acad. Sci. USA 109, 3463-3468 (2012).
96. Horuk, R. et al. Expression of chemokine receptors by subsets of neurons in the central nervous system. J. Immunol. 158, 2882-2890 (1997). (Pubitemid 127470549)
97. Yu, S., Crawford, D., Tsuchihashi, T., Behrens, T. W. & Srivastava, D. The chemokine receptor CXCR7 functions to regulate cardiac valve remodeling. D e v. Dyn. 240, 384-393 (2011).
98. Shimizu, S., Brown, M., Sengupta, R., Penfold, M. E. & Meucci, O. CXCR7 protein expression in human adult brain and differentiated neurons. PLoS ONE 6, e20680 (2011).
99. Tiveron, M.-C., Boutin, C., Daou, P., Moepps, B. & Cremer, H. Expression and function of CXCR7 in the mouse forebrain. J. Neuroimmunol. 224, 72-79 (2010).
100. Zimmerman, P. A., Ferreira, M. U., Howes, R. E. & Mercereau-Puijalon, O. Red blood cell polymorphism and susceptibility to Plasmodium vivax. Adv. Parasitol. 81, 27-76 (2013).
101. Tournamille, C., Colin, Y., Cartron, J. P. & Le Van Kim, C. Disruption of a GATA motif in the Duffy gene promoter abolishes erythroid gene expression in Duffy-negative individuals. Nature Genet. 10, 224-228 (1995).
102. Fukuma, N. et al. A role of the Duffy antigen for the maintenance of plasma chemokine concentrations. Biochem. Biophys. Res. Commun. 303, 137-139 (2003). (Pubitemid 36338218)
103. Mayr, F. B. et al. Duffy antigen modifies the chemokine response in human endotoxemia. Crit. Care Med. 36, 159-165 (2008).
104. Mayr, F. B. et al. Influence of the Duffy antigen on pharmacokinetics and pharmacodynamics of recombinant monocyte chemoattractant protein (MCP-1, CCL-2) in vivo. Int. J. Immunopathol. Pharmacol. 22, 615-625 (2009).
105. Jilma-Stohlawetz, P. et al. Fy phenotype and gender determine plasma levels of monocyte chemotactic protein. Transfusion 41, 378-381 (2001). (Pubitemid 32238538)
106. Darbonne, W. C. et al. Red blood cells are a sink for interleukin 8, a leukocyte chemotaxin. J. Clin. Invest. 88, 1362-1369 (1991).
107. Luo, H. et al. Cloning, characterization, and mapping of a murine promiscuous chemokine receptor gene: homolog of the human Duffy gene. Genome Res. 7, 932-941 (1997). (Pubitemid 27445380)
108. Serbina, N. V. & Pamer, E. G. Monocyte emigration from bone marrow during bacterial infection requires signals mediated by the chemokine receptor CCR2. Nature Immunol. 7, 311-317 (2006).
109. Cacalano, G. et al. Neutrophil and B cell expansion in mice that lack the murine IL-8 receptor homolog. Science 265, 682-684 (1994). (Pubitemid 24268283)
110. Schnabel, R. B. et al. Duffy antigen receptor for chemokines (Darc) polymorphism regulates circulating concentrations of monocyte chemoattractant protein-1 and other inflammatory mediators. Blood 115, 5289-5299 (2010).
111. Nalls, M. A. et al. Admixture mapping of white cell count: genetic locus responsible for lower white blood cell count in the Health ABC and Jackson Heart studies. Am. J. Hum. Genet. 82, 81-87 (2008). (Pubitemid 351726080)
112. Reich, D. et al. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet. 5, e1000360 (2009).
113. Crosslin, D. R. et al. Genetic variants associated with the white blood cell count in 13, 923 subjects in the eMERGE Network. Hum. Genet. 131, 639-652 (2011).
114. Grann, V. R. et al. Duffy (Fy), DARC, and neutropenia among women from the United States, Europe and the Caribbean. Br. J. Haematol. 143, 288-293 (2008).
115. Mei, J. et al. CXCL5 regulates chemokine scavenging and pulmonary host defense to bacterial infection. Immunity 33, 106-117 (2010).
116. Middleton, J. et al. Transcytosis and surface presentation of IL-8 by venular endothelial cells. Cell 91, 385-395 (1997). (Pubitemid 27467969)
117. Zarbock, A. et al. Chemokine homeostasis versus chemokine presentation during severe acute lung injury: the other side of the Duffy antigen receptor for chemokines. Am. J. Physiol. Lung Cell. Mol. Physiol. 298, L462-L471 (2010).
118. Zarbock, A. et al. The Duffy antigen receptor for chemokines in acute renal failure: a facilitator of renal chemokine presentation. Crit. Care Med. 35, 2156-2163 (2007). (Pubitemid 47326454)
119. Lee, J. S. et al. The Duffy antigen modifies systemic and local tissue chemokine responses following lipopolysaccharide stimulation. J. Immunol. 177, 8086-8094 (2006). (Pubitemid 44846327)
120. Luo, H., Chaudhuri, A., Zbrzezna, V., He, Y. & Pogo, A. O. Deletion of the murine Duffy gene (Dfy) reveals that the Duffy receptor is functionally redundant. Mol. Cell. Biol. 20, 3097-3101 (2000). (Pubitemid 30215022)
121. Dawson, T. C. et al. Exaggerated response to endotoxin in mice lacking the Duffy antigen/receptor for chemokines (DARC). Blood 96, 1681-1684 (2000). (Pubitemid 30661047)
122. Reutershan, J., Harry, B., Chang, D., Bagby, G. J. & Ley, K. DARC on RBC limits lung injury by balancing compartmental distribution of CXC chemokines. Eur. J. Immunol. 39, 1597-1607 (2009).
123. Vielhauer, V. et al. Efficient renal recruitment of macrophages and T cells in mice lacking the duffy antigen/receptor for chemokines. Am. J. Pathol. 175, 119-131 (2009).
124. Novitzky-Basso, I. & Rot, A. Duffy antigen receptor for chemokines and its involvement in patterning and control of inflammatory chemokines. Front. Immunol. 3, 266 (2012).
125. Ansel, K. M., Harris, R. B. S. & Cyster, J. G. CXCL13 is required for B1 cell homing, natural antibody production, and body cavity immunity. Immunity 16, 67-76 (2002). (Pubitemid 34143217)
126. high monocyte traffic and immunosuppressive activities by atypical chemokine receptor D6. Blood 119, 5250-5260 (2012).
127. Crosslin, D. R. et al. Genetic variation associated with circulating monocyte count in the eMERGE Network. Hum. Mol. Genet. 22, 2119-2127 (2013).
128. Graham, G. J. & Locati, M. Regulation of the immune and inflammatory responses by the 'atypical' chemokine receptor D6. J. Pathol. 229, 168-175 (2013).
129. Jamieson, T. et al. The chemokine receptor D6 limits the inflammatory response in vivo. Nature Immunol. 6, 403-411 (2005). (Pubitemid 41716781)
130. Martinez de la Torre, Y. et al. Increased inflammation in mice deficient for the chemokine decoy receptor D6. Eur. J. Immunol. 35, 1342-1346 (2005).
131. Whitehead, G. S. et al. The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity. Am. J. Respir. Crit. Care Med. 175, 243-249 (2007). (Pubitemid 46203127)
132. Codullo, V. et al. An investigation of the inflammatory cytokine and chemokine network in systemic sclerosis. Ann. Rheum. Dis. 70, 1115-1121 (2011).
133. Alexander-Sefre, F. et al. Clinical value of immunohistochemically detected lymphatic and vascular invasions in clinically staged endometrioid endometrial cancer. Int. J. Gynecol. Cancer 19, 1074-1079 (2009).
134. Lee, K. M. et al. D6 facilitates cellular migration, and fluid flow, to lymph nodes by suppressing lymphatic congestion. Blood 118, 6220-6229 (2011).
135. Lee, K. M., Nibbs, R. J. B. & Graham, G. J. D6: the 'crowd controller' at the immune gateway. Trends Immunol. 34, 7-12 (2012).
136. Liu, L. et al. Cutting edge: the silent chemokine receptor D6 is required for generating T cell responses that mediate experimental autoimmune encephalomyelitis. J. Immunol. 177, 17-21 (2006). (Pubitemid 43939108)
137. Cruz-Orengo, L. et al. CXCR7 antagonism prevents axonal injury during experimental autoimmune encephalomyelitis as revealed by in vivo axial diffusivity. J. Neuroinflamm. 8, 170 (2011).
138. Mazzinghi, B. et al. Essential but differential role for CXCR4 and CXCR7 in the therapeutic homing of human renal progenitor cells. J. Exp. Med. 205, 479-490 (2008). (Pubitemid 351281611)
139. Bunting, M. D., Comerford, I. & McColl, S. R. Finding their niche: chemokines directing cell migration in the thymus. Immunol. Cell Biol. 89, 185-196 (2010).
140. Braun, A. et al. Afferent lymph-derived T cells and DCs use different chemokine receptor CCR7-dependent routes for entry into the lymph node and intranodal migration. Nature Immunol. 12, 879-887 (2011).
141. Comerford, I. et al. The atypical chemokine receptor CCX-CKR scavenges homeostatic chemokines in circulation and tissues and suppresses Th17 responses. Blood 116, 4130-4140 (2010).
142. Miller, L. H., Mason, S. J., Clyde, D. F. & McGinniss, M. H. The resistance factor to Plasmodium vivax in blacks. The Duffy-blood-group genotype, FyFy. N. Engl. J. Med. 295, 302-304 (1976).
143. Allison, A. C. Genetic control of resistance to human malaria. Curr. Opin. Immunol. 21, 499-505 (2009).
144. b antigen polymorphism in human erythrocyte Duffy antigen affects susceptibility to Plasmodium vivax malaria. Proc. Natl Acad. Sci. USA 108, 20113-20118 (2011).
145. Miller, L. H., Mason, S. J., Dvorak, J. A., McGinniss, M. H. & Rothman, I. K. Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science 189, 561-563 (1975).
146. Tung, J. et al. Evolution of a malaria resistance gene in wild primates. Nature 460, 388-391 (2009).
147. Crosnier, C. et al. Basigin is a receptor essential for erythrocyte invasion by Plasmodium falciparum. Nature 480, 534-537 (2011).
148. McMorran, B. J. et al. Platelet factor 4 and Duffy antigen required for platelet killing of Plasmodium falciparum. Science 338, 1348-1351 (2012).
149. Lauer, S. et al. Vacuolar uptake of host components, and a role for cholesterol and sphingomyelin in malarial infection. EMBO J. 19, 3556-3564 (2000). (Pubitemid 30462114)
150. Samuel, B. U. et al. The role of cholesterol and glycosylphosphatidylinositol-anchored proteins of erythrocyte rafts in regulating raft protein content and malarial infection. J. Biol. Chem. 276, 29319-29329 (2001).
151. Szabo, M. C., Soo, K. S., Zlotnik, A. & Schall, T. J. Chemokine class differences in binding to the Duffy antigen-erythrocyte chemokine receptor. J. Biol. Chem. 270, 25348-25351 (1995).
152. Chaudhuri, A. et al. Expression of the Duffy antigen in K562 cells. Evidence that it is the human erythrocyte chemokine receptor. J. Biol. Chem. 269, 7835-7838 (1994).
153. Tang, Y.-Q., Yeaman, M. R. & Selsted, M. E. Antimicrobial peptides from human platelets. Infect. Immun. 70, 6524-6533 (2002). (Pubitemid 35387877)
154. Yeaman, M. R. et al. Modular determinants of antimicrobial activity in platelet factor-4 family kinocidins. Biochim. Biophys. Acta 1768, 609-619 (2007). (Pubitemid 46275592)
155. Lachgar, A. et al. Binding of HIV-1 to RBCs involves the Duffy antigen receptors for chemokines (DARC). Biomed. Pharmacother. 52, 436-439 (1998). (Pubitemid 29356644)
156. He, W. et al. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe 4, 52-62 (2008). (Pubitemid 351944053)
157. Kulkarni, H. et al. The Duffy-null state is associated with a survival advantage in leukopenic HIV-infected persons of African ancestry. Blood 114, 2783-2792 (2009).
158. Horne, K. C. et al. Duffy antigen polymorphisms do not alter progression of HIV in African Americans in the MACS cohort. Cell Host Microbe 5, 415-419 (2009).
159. Julg, B. et al. Lack of Duffy antigen receptor for chemokines: no influence on HIV disease progression in an African treatment-naive population. Cell Host Microbe 5, 413-415; author reply 418-419 (2009).
160. Walley, N. M. et al. The Duffy antigen receptor for chemokines null promoter variant does not influence HIV-1 acquisition or disease progression. Cell Host Microbe 5, 408-410; author reply 418-419 (2009).
161. Winkler, C. A., An, P., Johnson, R., Nelson, G. W. & Kirk, G. Expression of Duffy antigen receptor for chemokines (DARC) has no effect on HIV-1 acquisition or progression to AIDS in African Americans. Cell Host Microbe 5, 411-413; author reply 418-419 (2009).
162. Neil, S. J. D. et al. The promiscuous CC chemokine receptor D6 is a functional coreceptor for primary isolates of human immunodeficiency virus type 1 (HIV-1) and HIV-2 on astrocytes. J. Virol. 79, 9618-9624 (2005). (Pubitemid 41022305)
163. Shimizu, N. et al. A putative G protein-coupled receptor, RDC1, is a novel coreceptor for human and simian immunodeficiency viruses. J. Virol. 74, 619-626 (2000). (Pubitemid 30036197)
164. Wiederholt, T. et al. Genetic variations of the chemokine scavenger receptor D6 are associated with liver inflammation in chronic hepatitis C. Hum. Immunol. 69, 861-866 (2008).
165. Balkwill, F. Cancer and the chemokine network. Nature Rev. Cancer 4, 540-550 (2004). (Pubitemid 38868623)
166. Shen, H., Schuster, R., Stringer, K. F., Waltz, S. E. & Lentsch, A. B. The Duffy antigen/receptor for chemokines (DARC) regulates prostate tumor growth. FASEB J. 20, 59-64 (2006). (Pubitemid 43100476)
167. Addison, C. L., Belperio, J. A., Burdick, M. D. & Strieter, R. M. Overexpression of the duffy antigen receptor for chemokines (DARC) by NSCLC tumor cells results in increased tumor necrosis. BMC Cancer 4, 28 (2004).
168. Wang, J. H. et al. Enhanced expression of Duffy antigen receptor for chemokines by breast cancer cells attenuates growth and metastasis potential. Oncogene 25, 7201-7211 (2006).
169. Horton, L. W., Yu, Y., Zaja-Milatovic, S., Strieter, R. M. & Richmond, A. Opposing roles of murine duffy antigen receptor for chemokine and murine CXC chemokine receptor-2 receptors in murine melanoma tumor growth. Cancer Res. 67, 9791-9799 (2007). (Pubitemid 47621226)
170. Elson, J. K. et al. The Duffy antigen/receptor for chemokines (DARC) and prostate-cancer risk among Jamaican men. J. Immigr. Minor. Health 13, 36-41 (2010).
171. Bandyopadhyay, S. et al. Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nature Med. 12, 933-938 (2006). (Pubitemid 44175145)
172. Schneider, C. et al. Adaptive immunity suppresses formation and progression of diethylnitrosamine-induced liver cancer. Gut 61, 1733-1743 (2012).
173. Wu, F.-Y. et al. Chemokine decoy receptor D6 plays a negative role in human breast cancer. Mol. Cancer Res. 6, 1276-1288 (2008).
174. McKimmie, C. S. et al. An analysis of the function and expression of D6 on lymphatic endothelial cells. Blood 121, 3768-3777 (2013).
175. Cancian, L., Hansen, A. & Boshoff, C. Cellular origin of Kaposi's sarcoma and Kaposi's sarcoma-associated herpesvirus-induced cell reprogramming. Trends Cell Biol. 23, 421-432 (2013).
176. Ma, M., Ye, J. Y., Deng, R., Dee, C. M. & Chan, G. C.-F. Mesenchymal stromal cells may enhance metastasis of neuroblastoma via SDF-1/CXCR4 and SDF-1/CXCR7 signaling. Cancer Lett. 312, 1-10 (2011).
177. Calatozzolo, C. et al. Expression of the new CXCL12 receptor, CXCR7, in gliomas. Cancer Biol. Ther. 11, 242-253 (2011).
178. Zheng, K. et al. Chemokine receptor CXCR7 regulates the invasion, angiogenesis and tumor growth of human hepatocellular carcinoma cells. J. Exp. Clin. Cancer Res. 29, 31 (2010).
179. Xue, T.-C. et al. Down-regulation of CXCR7 inhibits the growth and lung metastasis of human hepatocellular carcinoma cells with highly metastatic potential. Exp. Ther. Med. 3, 117-123 (2012).
180. Yao, X., Zhou, L., Han, S. & Chen, Y. High expression of CXCR4 and CXCR7 predicts poor survival in gallbladder cancer. J. Int. Med. Res. 39, 1253-1264 (2011).
181. Iwakiri, S. et al. Higher expression of chemokine receptor CXCR7 is linked to early and metastatic recurrence in pathological stage I nonsmall cell lung cancer. Cancer 115, 2580-2593 (2009).
182. Yates, T. J. et al. C-X-C chemokine receptor 7: a functionally associated molecular marker for bladder cancer. Cancer 119, 61-71 (2013).
183. Hao, M. et al. Role of chemokine receptor CXCR7 in bladder cancer progression. Biochem. Pharmacol. 84, 204-214 (2012).
184. Liu, Z. et al. Expression of stromal cell-derived factor 1 and CXCR7 in papillary thyroid carcinoma. Endocr. Pathol. 23, 247-253 (2012).
185. Hassan, S. et al. The influence of tumor-host interactions in the stromal cell-derived factor-1/CXCR4 ligand/receptor axis in determining metastatic risk in breast cancer. Am. J. Pathol. 175, 66-73 (2009).
186. Schrevel, M. et al. CXCR7 expression is associated with disease-free and disease-specific survival in cervical cancer patients. Br. J. Cancer 106, 1520-1525 (2012).
187. Wang, J. et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J. Biol. Chem. 283, 4283-4294 (2008).
188. Hernandez, L., Magalhaes, M. A. O., Coniglio, S. J., Condeelis, J. S. & Segall, J. E. Opposing roles of CXCR4 and CXCR7 in breast cancer metastasis. Breast Cancer Res. 13, R128 (2011).
189. Zabel, B. A., Lewén, S., Berahovich, R. D., Jaen, J. C. & Schall, T. J. The novel chemokine receptor CXCR7 regulates trans-endothelial migration of cancer cells. Mol. Cancer 10, 73 (2011).
190. Nomiyama, H., Osada, N. & Yoshie, O. Systematic classification of vertebrate chemokines based on conserved synteny and evolutionary history. Genes Cells 18, 1-16 (2013).
191. Zlotnik, A. & Yoshie, O. Chemokines: a new classification system and their role in immunity. Immunity 12, 121-127 (2000). (Pubitemid 30398626)
192. David, N. B. et al. Molecular basis of cell migration in the fish lateral line: role of the chemokine receptor CXCR4 and of its ligand, SDF1. Proc. Natl Acad. Sci. USA 99, 16297-16302 (2002). (Pubitemid 35462789)
193. Valentin, G., Haas, P. & Gilmour, D. The chemokine SDF1a coordinates tissue migration through the spatially restricted activation of Cxcr7 and Cxcr4b. Curr. Biol. 17, 1026-1031 (2007). (Pubitemid 46899533)
194. Dambly-Chaudière, C., Cubedo, N. & Ghysen, A. Control of cell migration in the development of the posterior lateral line: antagonistic interactions between the chemokine receptors CXCR4 and CXCR7/RDC1. BMC Dev. Biol. 7, 23 (2007).
195. Boldajipour, B. et al. Control of chemokine-guided cell migration by ligand sequestration. Cell 132, 463-473 (2008). (Pubitemid 351191997)
196. Nagasawa, T. et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382, 635-638 (1996). (Pubitemid 26268957)
197. Zou, Y. R., Kottmann, A. H., Kuroda, M., Taniuchi, I. & Littman, D. R. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature 393, 595-599 (1998). (Pubitemid 28319251)
198. Haege, S. et al. CXC-chemokine receptor 7 (CXCR7) regulates CXCR4 protein expression and capillary tuft development in mouse kidney. PLoS ONE 7, e42814 (2012).
199. Cubedo, N., Cerdan, E., Sapède, D. & Rossel, M. CXCR4 and CXCR7 cooperate during tangential migration of facial motoneurons. Mol. Cell. Neurosci. 40, 474-484 (2009).
200. Zhu, B. et al. CXCL12 enhances human neural progenitor cell survival through a CXCR7-and CXCR4-mediated endocytotic signaling pathway. Stem Cells 30, 2571-2583 (2012).